Try our Advanced Search for more refined results
Life Sciences
-
March 30, 2026
Don't Set Special IP Rules For 'Skinny Labels,' Justices Told
Drugmakers, industry groups, hospitals and scholars have urged the U.S. Supreme Court to uphold a decision letting a patent suit proceed over a generic drug using a so-called skinny label, saying the generics company is seeking unwarranted special protections that would upend patent law.
-
March 30, 2026
FCA Qui Tams Are Unconstitutional, Eli Lilly Tells Justices
The False Claims Act's whistleblower provisions are unconstitutional, drugmaker Eli Lilly has told the U.S. Supreme Court, asking it to overturn a Seventh Circuit decision upholding a $183 million trial win for a whistleblower who claimed the drug company hid how much it charged for Medicaid-covered drugs.
-
March 30, 2026
Sanofi Claims IP Life Extension Needed For Double Patenting
The Patent Trial and Appeal Board rightly found a Sanofi patent application shouldn't be rejected for obviousness-type double patenting, as it doesn't improperly extend patent life, the French drugmaker and its allies have told U.S. Patent and Trademark Office Director John Squires.
-
March 30, 2026
Cleary-Led Blackstone Wraps Record $6.3B Life Sci Fund
Private equity giant Blackstone, led by Cleary Gottlieb Steen & Hamilton LLP, revealed Monday that it wrapped its sixth life sciences fund after securing $6.3 billion of capital commitments, marking what the firm says is the largest private life sciences fund ever raised.
-
March 30, 2026
Eli Lilly's $2.75B Pact Is Latest In AI Drug Discovery Push
Eli Lilly and Co. has agreed to a partnership with artificial intelligence-driven drug discovery company Insilico that could be worth up to $2.75 billion, amid an expanding category of collaboration fueled by pharmaceutical giants seeking accelerated paths to new treatments.
-
March 30, 2026
Del. Judge Upholds $34M Verdict In Glaucoma Patent Feud
A Delaware federal judge has affirmed a $34 million verdict against Alcon and related entities for infringing patents covering medical devices to treat glaucoma, disagreeing that Sight Sciences Inc. had failed to show the accused product meets the limitations of the patent claims.
-
March 30, 2026
J&J Unit Wants Forensic Exam Of Ex-Director's Devices
A Johnson & Johnson subsidiary urged a New Jersey federal court to order a former associate director to submit to a court-supervised forensic inspection of any device or account in which she could have stored confidential information it claims she downloaded in order to start her own competing company.
-
March 30, 2026
Eagle Pharma To Pay $9.5M To End Channel Stuffing Claims
Eagle Pharmaceuticals Inc. and its former executives have agreed to pay $9.5 million to settle investor claims that they carried out a fraudulent "channel stuffing" scheme to inflate the revenue of one of the company's brand-name medications.
-
March 30, 2026
High Court Turns Away CRISPR Patent Validity Dispute
The U.S. Supreme Court on Monday rejected Agilent Technologies' bid to revive patents on the gene-editing tool CRISPR, which centers on the burden of proof in establishing prior art.
-
March 30, 2026
Justices Pass On FCA Suit Alleging Quest Diagnostics Fraud
The U.S. Supreme Court rejected on Monday a former Quest Diagnostics Inc. compliance officer's bid for review of the dismissal of a long-running False Claims Act suit against the medical testing company.
-
March 30, 2026
Justices Reject TM Appeal Tied To 'Use In Commerce'
The U.S. Supreme Court on Monday declined to take up an appeal challenging a Ninth Circuit ruling that upheld a multimillion-dollar default judgment based largely on statements defendants made in trademark applications.
-
March 27, 2026
Elizabeth Holmes Gets 11-Year Prison Sentence Cut By A Year
A California federal judge has shaved off a year from convicted ex-Theranos CEO Elizabeth Holmes' 11-year-and-three-month prison sentence for securities fraud due to recent sentencing guideline amendments, reducing her time behind bars by one year, instead of the two years she requested, amid objections by prosecutors.
-
March 27, 2026
Eli Lilly Keeps Most Of Weight Loss Drug Copy Suit Alive
A California federal judge has refused to throw out a lawsuit accusing a pair of telehealth companies of making copies of Eli Lilly's obesity and type 2 diabetes drugs but agreed to trim the case.
-
March 27, 2026
Del. Justices Won't Revive Hedge Fund Insider Trading Case
The Delaware Supreme Court upheld a ruling Friday in favor of hedge fund Armistice Capital, backing the dismissal of a lawsuit accusing the firm of insider trading on information it had obtained in its position as a minority stakeholder of a pharmaceutical company.
-
March 27, 2026
Hospital System Beats Most Of REIT's $50M Floodwall Suit
A New York federal judge on March 27 mostly tossed a real estate investment trust's $50 million suit against the New York City Health and Hospitals Corp. and the NYC Economic Development Corp. over the design of a proposed floodwall for a downtown Manhattan life sciences campus project.
-
March 27, 2026
Nobel Prize Winners Again Lose Patent Fight Over CRISPR
The Patent Trial and Appeal Board has ruled against a pair of Nobel Prize-winning scientists in a patent dispute over who was the first to invent key aspects of the gene-editing technology CRISPR, siding again with a rival team from the Broad Institute and the Massachusetts Institute of Technology.
-
March 27, 2026
Skincare Co. Says ITC Ruling Backs Ending PTAB Challenge
Skin products company Hydrafacial has argued U.S. Patent and Trademark Office Director John Squires should turn down a rehearing request from rival Sinclair Pharma over Squires' order de-instituting a challenge to Hydrafacial's patent, saying a U.S. International Trade Commission decision upholding the same patent supports the director's move.
-
March 27, 2026
Sens. Push Bill To Equip VA For Psychedelic Therapies
A bipartisan group of U.S. senators has introduced legislation to broaden veterans' access to emerging therapies, including psychedelic-assisted treatments, that may be effective in addressing post-traumatic stress disorder and other mental health issues.
-
March 27, 2026
Biopharma's Brass Hid Anxiety Drug Trial Risks, Investor Says
Vistagen Therapeutics' current and former top brass have been hit with a derivative shareholder suit in California federal court alleging they overstated its clinical trial for a novel, anti-anxiety drug while hiding unpredictable placebo responses and other known risks, before the phase ultimately failed, causing a stock price collapse.
-
March 27, 2026
Biogen Beats Investor Suit Over Dozens Of Drug Claims
Biogen Inc. and four of its executives escaped a stock drop suit Friday after a Massachusetts federal judge ruled that none of the nearly five dozen statements challenged by investors suggested that the company intentionally misled people buying its stock.
-
March 27, 2026
Mississippi Gov. Vetoes Medical Marijuana Expansion Bill
Mississippi Gov. Tate Reeves has vetoed a bill to expand the state's medical cannabis program to include severely ill patients, while approving another bill to fund a clinical trial into the psychedelic ibogaine.
-
March 27, 2026
NJ Federal Judge DQs Beasley Allen In J&J Talc MDL
A New Jersey federal judge has disqualified the Beasley Allen Law Firm from representing hundreds of plaintiffs in sprawling multidistrict litigation over Johnson & Johnson's talc-based baby powder, holding that the firm violated ethics rules by collaborating with former outside counsel for J&J, a ruling the law firm has vowed to appeal.
-
March 27, 2026
Pharma Co. Says Exec Was Fired Over Conduct, Not Piglets
The U.S. arm of a Danish pharmaceutical company has told a North Carolina federal judge to throw out a former director's "extraordinary and conspiratorial" lawsuit claiming he was fired for expressing concerns about his employer's use of piglets at an anniversary party.
-
March 27, 2026
Kirkland-Led Transcend Bought By Otsuka In $1.2B Deal
Clinical-stage biotechnology company Transcend Therapeutics Inc., led by Kirkland & Ellis LLP, Pillsbury Winthrop Shaw Pittman LLP and Goodwin Procter LLP, on Friday announced that it has agreed to be bought by Otsuka Pharmaceutical Co. Ltd. in a deal worth up to $1.225 billion.
-
March 26, 2026
Elanco Beats Investor Suit Over Dog Drug's Reg Challenges
A Maryland federal judge Thursday dismissed a proposed securities class action against Elanco Animal Health Inc. that claimed the animal pharmaceuticals company misled investors about the safety of a canine dermatitis treatment it was developing and its timeline for the medication's commercial launch.
Expert Analysis
-
Series
Playing Tennis Makes Me A Better Lawyer
An instinct to turn pain into purpose meant frequent trips to the tennis court, where learning to move ahead one point at a time was a lesson that also applied to the steep learning curve of patent prosecution law, says Daniel Henry at Marshall Gerstein.
-
Expect Major Shifts In Patent And Trademark Policy This Year
New leadership and initiatives promise to bring consequential changes to the U.S. Patent and Trademark Office's practices in 2026, likely favoring patent allowance and issuance, as well as streamlining trademark processes, say attorneys at Knobbe Martens.
-
Class Actions At The Circuit Courts: January Lessons
In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five rulings from October and November, and identifies practice tips from cases involving consumer fraud, oil and gas leases, toxic torts, and wage and hour issues.
-
Series
Judges On AI: How Judicial Use Informs Guardrails
U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.
-
What US Cos. Must Know To Comply With Italy's AI Law
Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.
-
Ag Bill Wording Presents Existential Threat To Hemp Industry
A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.
-
Series
Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief
My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.
-
5 Drug Pricing Policy Developments To Watch In 2026
2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.
-
Patent Applicants Must Get Biologics Enablement Right
As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.
-
Series
Law School's Missed Lessons: How To Start A Law Firm
Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.
-
Fed. Circ. Patent Decisions In 2025: An Empirical Review
In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.
-
Regulatory Uncertainty Ahead For Organ Transplant System
Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.
-
Key False Claims Act Trends From The Last Year
The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.
-
Opinion
It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs
The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.
-
Series
Hosting Exchange Students Makes Me A Better Lawyer
Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.